Northstar Financial Companies Inc. bought a new position in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,226 shares of the company's stock, valued at approximately $277,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock valued at $379,000 after buying an additional 2,789 shares in the last quarter. Blue Trust Inc. grew its holdings in AstraZeneca by 38.4% during the 4th quarter. Blue Trust Inc. now owns 27,712 shares of the company's stock valued at $1,816,000 after buying an additional 7,686 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in AstraZeneca by 3.0% during the 4th quarter. Perigon Wealth Management LLC now owns 19,597 shares of the company's stock valued at $1,311,000 after buying an additional 567 shares in the last quarter. Orca Wealth Management LLC purchased a new stake in AstraZeneca during the 4th quarter valued at approximately $4,532,000. Finally, R Squared Ltd purchased a new stake in AstraZeneca during the 4th quarter valued at approximately $111,000. 20.35% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley assumed coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating for the company. Finally, BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $85.00.
Get Our Latest Research Report on AZN
AstraZeneca Price Performance
Shares of NASDAQ AZN traded up $1.95 during midday trading on Friday, reaching $72.82. 8,033,731 shares of the stock traded hands, compared to its average volume of 5,194,017. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. The stock has a market capitalization of $225.83 billion, a PE ratio of 32.22, a P/E/G ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company's 50 day moving average is $69.38 and its 200 day moving average is $69.67.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. AstraZeneca's revenue was up 7.2% on a year-over-year basis. During the same period last year, the company earned $2.06 earnings per share. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
